

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
C. Roland Wolf	01/26/2010
Colin J. Henderson	01/26/2010
RECEIVING PARTY DATA	
Name:	Cancer Research Technology Limited
Street Address:	Sardinia House
Internal Address:	Sardinia Street
City:	London
State/Country:	UNITED KINGDOM
Postal Code:	WC2A 3NL
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	10306559
CORRESPONDENCE DATA	
Fax Number:	(919)854-1401
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	919-854-1400
Email:	msalazar@myersbigel.com
Correspondent Name:	MBSS / Marthenn Salazar
Address Line 1:	4140 Parklake Ave
Address Line 2:	Suite 600
Address Line 4:	Raleigh, NORTH CAROLINA 27612
ATTORNEY DOCKET NUMBER:	9052-137
NAME OF SUBMITTER:	Marthenn Salazar
Total Attachments: 4 source=QuitclaimAssignment#page1.tif	

CH \$40.00 10306559

501102220

PATENT
REEL: 023988 FRAME: 0694

source=QuitclaimAssignment#page2.tif
source=QuitclaimAssignment#page3.tif
source=QuitclaimAssignment#page4.tif

QUITCLAIM ASSIGNMENT

THIS QUITCLAIM ASSIGNMENT, made by **C. Roland Wolf**, an individual having a mailing address at University of Dundee Biomedical Research Institute, Ninewells Hospital & Medical School, Dundee DD1 9SY, United Kingdom, and **Colin J. Henderson**, an individual having a mailing address at University of Dundee Biomedical Research Institute, Ninewells Hospital & Medical School, Dundee DD1 9SY, United Kingdom, hereinafter referred to as assignors;

WITNESSETH: That,

WHEREAS, the above-named assignors may have a right, title, and interest in and to certain new and useful improvements in **MODULATION OF CYTOCHROME P450 REDUCTASE ACTIVITY**, for which a non-provisional application was filed on **November 22, 2002** and assigned U.S. Application No. **10/306,559**; and

WHEREAS, **Cancer Research Technology Limited**, a United Kingdom corporation having a principal place of business at Sardinia House, Sardinia Street, London WC2A 3NL, United Kingdom (formerly known as Imperial Cancer Research Technology Limited), hereinafter referred to as assignee, is desirous of acquiring the right, title, and interest, if any, in and to said invention as described in said non-provisional application, and in and to any and all Letters Patent which shall be granted therefor in the United States of America and all foreign countries;

NOW, THEREFORE, To All Whom It May Concern, be it known that for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the above assignors have sold and by these presents do hereby sell, assign, transfer, and convey unto the said assignee, its successors and assigns, its entire right, title, and interest, if any, in and to the said invention and non-provisional application, and in and to any and all subsequent patent applications which claim the benefit of priority from said non-provisional application including regular utility, continuations, and continuations-in-part, or divisions thereof, and in and to any and all Letters Patent of the United States of America and all foreign countries or reissues or other forms of protection thereof which may be granted for the invention in or on applications claiming the benefit of priority from said non-provisional application, for the full end of the term for which said Letters Patent may be granted along with any term extensions thereof or therefor, together with the right to claim the benefit of priority from said application in all foreign

countries in accordance with the International Convention, the same to be held and enjoyed by said assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by assignors if this assignment and sale had not been made.

The assignors further covenant and agree to promptly communicate to said assignee or its representatives any facts known to the assignors relating to said invention, to testify in any interference or legal proceedings involving said invention, to execute any additional papers which may be requested to confirm the right of the assignee, its representatives, successors, or assigns to secure patent or similar protection for the said invention in all countries and to vest in the assignee complete title to the said invention and Letters Patent, without further compensation, but at the expense of said assignee, its successors, assigns, and other legal representatives; and the assignors hereby instruct, and further covenant and agree to bind its legal representatives and assigns, to do same, without further compensation, but at the expense of said assignee or its representatives.

IN WITNESS WHEREOF, I have hereunto set my hand and seal on this 26th day of January, 2010.

ASSIGNOR:

C. Roland Wolf

Witnessed by:

Margaret Rooney (MARGARET ROONEY)

Date: 26/1/2010

Lisa Thompson (LISA THOMPSON)

Date: 26/1/2010

IN WITNESS WHEREOF, I have hereunto set my hand and seal on this 26th day of January, 2010.

ASSIGNOR:

Colin J. Henderson

Witnessed by:


MARGARET ROONEY Margaret Rooney

Date: 26/1/2010


Lisa Thompson (LISA THOMPSON)

Date: 26/1/2010

IN WITNESS WHEREOF, I have hereunto set my hand and seal on this 17th day of February, 2010.

Cancer Research Technology Limited:
By: 
Print Name: P J L'Hullier
Title: Director, Business Management

Witnessed by:

Ann Dixon 
Date: 17/2/2010

Date: _____